Traitement systémique des métastases cérébrales de mélanome
| Autor: | M. Thomas, C. Lebbé, F. Dhermain, Thomas Jouary, Cédric Robert, L. Mortier, J.-J. Grob, E. Le Rhun, Christine Mateus, Bernard Guillot, Marie-Thérèse Leccia |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0303 health sciences
business.industry Kinase Melanoma medicine.medical_treatment Ipilimumab Immunotherapy medicine.disease 3. Good health Serine Radiation therapy 03 medical and health sciences 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Cancer research Medicine Cytotoxic T cell Radiology Nuclear Medicine and imaging Protein kinase A business 030304 developmental biology medicine.drug |
| Zdroj: | Cancer/Radiothérapie. 19:48-54 |
| ISSN: | 1278-3218 |
| Popis: | Melanomas have a high rate of brain metastases. Both the functional prognosis and the overall survival are poor in these patients. Until now, surgery and radiotherapy represented the two main modalities of treatment. Nevertheless, due to the improvement in the management of the extracerebral melanoma, the systemic treatment may be an option in patients with brain metastases. Immunotherapy with anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) - ipilimumab - or BRAF (serine/threonine-protein kinase B-raf) inhibitors - vemurafenib, dabrafenib - has shown efficacy in the management of brain metastases in a- or pauci-symptomatic patients. Studies are ongoing with anti-PD1 (programmed cell death 1) and combinations of targeted therapies associating anti-RAF (raf proto-oncogene, serine/threonine kinase) and anti-MEK (mitogen-activated protein kinase kinase). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect